Key result
Perioperative midazolam administration was not associated with an overall risk of myocardial injury in non-cardiac surgery (OR 0.98), but significantly increased risk during overnight surgeries.
Why the study?
It was hypothesized that perioperative midazolam administration is associated with an increased incidence of myocardial injury after non-cardiac surgery (MINS) and that circadian biology may underlie this relationship.
Does perioperative midazolam administration increase the risk of myocardial injury in patients undergoing non-cardiac surgery?
Observational (n=1,773,118)
Yes
Does perioperative midazolam administration increase the risk of myocardial injury in patients undergoing non-cardiac surgery?
Odds Ratio: 0.98 (95% CI 0.94–1.01)
Absolute Event Rate: 0.77% vs 1.1%
While perioperative midazolam does not increase the overall risk of myocardial injury in non-cardiac surgery, it may significantly increase risk during overnight surgeries, suggesting a circadian-dependent effect.
Background: circadian-mediated mechanisms. We hypothesized that perioperative midazolam administration is associated with an increased incidence of myocardial injury in patients undergoing non-cardiac surgery (MINS) and that circadian biology may underlie this relationship. Methods: We analyzed intraoperative data from the Multicenter Perioperative Outcomes Group for the occurrence of MINS across 50 institutions from 2014 to 2019. The primary outcome was the occurrence of MINS. MINS was defined as having at least one troponin-I lab value ≥0.03 ng/ml from anesthesia start to 72 h after anesthesia end. To account for bias, propensity scores and inverse probability of treatment weighting were applied. Results: A total of 1,773,118 cases were available for analysis. Of these subjects, 951,345 (53.7%) received midazolam perioperatively, and 16,404 (0.93%) met criteria for perioperative MINS. There was no association between perioperative midazolam administration and risk of MINS in the study population as a whole (odds ratio (OR) 0.98, confidence interval (CI) [0.94, 1.01]). However, we found a strong association between midazolam administration and risk of MINS when surgery occurred overnight (OR 3.52, CI [3.10, 4.00]) or when surgery occurred in ASA 1 or 2 patients (OR 1.25, CI [1.13, 1.39]). Conclusion: Perioperative midazolam administration may not pose a significant risk for MINS occurrence. However, midazolam administration at night and in healthier patients could increase MINS, which warrants further clinical investigation with an emphasis on circadian biology.
No takes yet. Share an insight, caveat, or question.
Prin et al. (2022) conducted an observational in Non-cardiac surgery (n=1,773,118). Perioperative midazolam administration vs. No perioperative midazolam administration was evaluated on Occurrence of myocardial injury in non-cardiac surgery (MINS), defined as at least one troponin-I lab value ≥0.03 ng/ml from anesthesia start to 72 h after anesthesia end (OR 0.98, 95% CI 0.94, 1.01). Perioperative midazolam administration was not associated with an overall risk of myocardial injury in non-cardiac surgery (OR 0.98), but significantly increased risk during overnight surgeries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: